Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates

Published on 9 May 2024 on Zacks via Yahoo Finance

Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates

Mirum Pharmaceuticals, Inc. MIRM incurred first-quarter 2024 loss of 54 cents per share, wider than the Zacks Consensus Estimate of a loss of 40 cents. The company had reported a loss of 80 cents per share in the year-ago quarter.

Revenues in the first quarter totaled $69.2 million, up almost 118.9% year over year. The figure, however, missed the Zacks Consensus Estimate of $70 million. The top line comprised Livmarli (maralixibat) sales, newly acquired Cholbam and Chenodal sales and minimal license and other revenues.

Read the rest of the article

NASDAQ.HLIT price evolution

NASDAQ.MIRM price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

News

Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates

NASDAQ.HLIT price evolution

NASDAQ.MIRM price evolution

Want to become a better investor?

Zacks Industry Outlook Highlights Arista Networks, Corning and Harmonic

Is Weakness In Harmonic Inc. (NASDAQ:HLIT) Stock A Sign That The Market Could be...

Harmonic Inc (NASDAQ:HLIT): A Bull Case Theory

Harmonic (HLIT) Collaborates With 44p to Enhance UHD Playout

Is Harmonic Inc.'s (NASDAQ:HLIT) Recent Stock Performance Tethered To Its Strong Fundamentals?

Insider Sale: CEO Natalie Holles Sells Shares of Third Harmonic Bio Inc (THRD)

Stock market: What is the secret of the top performers?

Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates

Harmonic Inc. (NASDAQ:HLIT) Q1 2024 Earnings Call Transcript

Royce Micro-Cap Trust (NYSE: RMT) as of Mar 31, 2024